Long-term effects of time-restricted eating on liver health in people with metabolic fatty liver disease

Durable improvement of hepatic steatosis and fibrosis with time-restricted eating in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis: a long-term comparative observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN74413912

Enrollment

203

Registered

2026-01-26

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), hepatic steatosis, liver fibrosis, metabolic dysfunction Digestive System

Interventions

This is a prospective observational cohort study. Adults with metabolic dysfunction–associated steatotic liver disease (MASLD) or metabolic dysfunction–associated steatohepatitis (MASH) were enrolled

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18–65 years 2. Diagnosis of metabolic dysfunction–associated steatotic liver disease (MASLD) or metabolic dysfunction–associated steatohepatitis (MASH) 3. Evidence of hepatic steatosis defined by: 4. Imaging (ultrasonography) and/or FibroScan® controlled attenuation parameter (CAP) =248 dB/m 5. Presence of at least one metabolic risk factor (e.g. overweight/obesity, type 2 diabetes, dyslipidaemia, hypertension) 6. For MASH: elevated aminotransferases with concordant FibroScan® liver stiffness measurement (LSM) =8 kPa 7. Ability and willingness to provide written informed consent 8. Willingness to participate in longitudinal follow-up

Exclusion criteria

Exclusion criteria: 1. Chronic viral hepatitis (hepatitis B or C) 2. Autoimmune liver disease or cholestatic liver disease 3. Genetic or metabolic liver diseases (e.g. hemochromatosis, Wilson disease) 4. Drug-induced liver injury or use of known hepatotoxic medications 5. Decompensated cirrhosis or clinical evidence of portal hypertension 6. Active malignancy 7. Pregnancy or breastfeeding 8. Severe or unstable cardiovascular disease 9. Acute systemic illness at the time of enrollment 10. Significant alcohol intake 11. Inability to comply with follow-up or lifestyle intervention protocols 12. Prior bariatric surgery or planned bariatric surgery during the study period

Countries

Egypt, India, Jordan, Philippines, Saudi Arabia, Tunisia

Contacts

Public ContactAhmed Al Badrani

ahmedthanaa952@gmail.com+966 (0)594875700

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 27, 2026